



Drug Utilization Review Board Meeting Minutes

September 14, 2021

Webex and In-person Meeting

DUR Board Members in attendance: Kevin Borchert, RP; Tim Bourke, RP; Charlie Moore, RP; David Randolph, RP; Phil Vuchetich, RP;

DUR Board Member not in attendance: Bruce Houghton, MD, Susan Howard, MD, Robert Wergin, MD, Anthony Ross, MD.

DHHS attendees: Leah Spencer, RN; Dianne Garside, RP; Spencer Moore, RP; Ken Saunders, RP;

Contracted attendees: Nikia Bennette-Carter, RP, Magellan Rx Management, Jenni Pandak, Magellan RX Management; Jamie Benson, RP, Nebraska Total Care; Maria Martin, RP, Nebraska Total Care; Shannon Nelson, RP, Healthy Blue Nebraska; Bernadette Ueda, RP, United Health Care.

Numerous Public visitors were in attendance per Webex webinar.

I. Call to Order:

The meeting was called to order by Ken Saunders on September 14, 2021 at 6:30 pm CDT. Members and attendees were welcomed. The Open-Meetings Act was reviewed and made known as available on the NE Medicaid pharmacy website. Initially, there was not a quorum. However at 23 minutes into the meeting, Dave Randolph joined the meeting and this fulfilled the quorum requirement for voting.

II. Conflict of Interest

No conflicts of interest were declared.

III. Agenda approval

The September 14, 2021 meeting agenda was presented and approved. Unanimous vote in the affirmative for accepting the Agenda as written.

IV. Meeting Minutes from the July 13, 2021 Meeting

The DUR Board reviewed the previous DUR Board meeting minutes from July 2021. Motion by Borchers and second by Bourke to approve the minutes. The minutes for the meeting were voted upon and passed by the DUR Board members in attendance.

V. Update on SUPPORT Act Data

Spencer Moore presented slides reviewing the SUPPORT Act data and how Nebraska compares to other states in the country. Different sections of the SUPPORT Act were presented. This included MME limits, benzodiazepines, antipsychotics, and gabapentin or pregabalin. Tim Bourke questioned the numbers from the other states that had higher limits. Moore reassured the group that the other states do leave out the hospice patients as per the definition of SUPPORT Act medication reporting. The next full review of SUPPORT Act data will be in the Spring of 2022.

VII. Prospective DUR / New Project Requests

Dianne Garside reported on the updated Immunomodulator PA form. She discussed the enhancements to the form. Included in the discussion was the support from the MCO's of the PA form and the acknowledgement that they may use their own PA form as long as the form contains the same criteria for approval.

Ivermectin use was discussed and the possibility of any DUR Board projects were discussed. The use of any medications not indicated or approved by the FDA were mentioned by the group. Kevin Borchers commented that only with an approved FDA indication, should Medicaid pay for the use. A further discussion was had that included the possibility of adding a PA form or template if the parties are so inclined. This will be discussed further after the DHHS reviews the utilization data.

VIII. Future Meeting Dates

The next DUR Board meeting will be Tuesday November 9, 2021. Saunders reminded everyone that the November meeting will probably be an in-person and virtual event. Watch the DUR Board website for the WEBEX meeting information, the Agenda and the DRAFT Minutes. The meeting will begin at 6:30 PM CST.

IX. Concerns & Comments

There were no concerns or comments by any of the DUR Board members, DHHS Staff, MCO's, or Public members

X. Adjournment

The meeting was adjourned without reservation. The meeting was adjourned at 7:19 PM.